IO Biotech (IOBT) Price & Analysis

Compare

451 Followers

IOBT Stock Chart & Stats

$0.90

-$0.03(-3.11%)

At close: Jan 08 4:00 PM EST

$0.90

-$0.03(-3.11%)

Day’s Range― - ―

52-Week Range$0.32 - $2.79

Previous CloseN/A

Volume57.25K

Average Volume (3M)6.73M

Market Cap

$55.54M

Enterprise ValueN/A

Total Cash (Recent Filing)$28.13M

Total Debt (Recent Filing)$8.36M

Price to Earnings (P/E)―

Beta1.11

Next Earnings

Nov 05, 2025

EPS Estimate

-0.31

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.40

Shares Outstanding65,880,910

10 Day Avg. Volume1,259,505

30 Day Avg. Volume6,727,141

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)1.29

Price to Sales (P/S)0.00

P/FCF Ratio-0.74

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$1.70

Price Target Upside88.89% Upside

Rating ConsensusHold

Number of Analyst Covering4

EPS Forecast (FY)-1.25

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsThe new combo therapy showed an improvement in PFS across nearly all patient subgroups, except in patients who had prior exposure to anti-PD-(L)1 therapies.

Financial PositionThe company ended 2Q25 with $28M and recently added $14.4M (second loan facility tranche), which combined is expected to support operations into 1Q26.

Regulatory StrategyThe management intends to file for approval by the end of the year and is seeking Priority Review, indicating a proactive strategy despite challenges.

Bears Say

FDA RecommendationsFDA recommends company not submit BLA based on Ph3 melanoma data.

Financial ConstraintsThe company is facing a tight cash position with approximately $38 million available, raising concerns about its financial runway.

Workforce RestructuringAnnounces restructuring including a 50% head count reduction.

IO Biotech News

IO Biotech presents pre-clinical data on IO112, IO170

IO Biotech (IOBT) announced new pre-clinical data for IO Biotech’s next vaccine candidate, IO112, and additional candidate, IO170,...

3d ago

IOBT

IO Biotech price target lowered to $3 from $10 at Piper Sandler

Piper Sandler lowered the firm’s price target on IO Biotech (IOBT) to $3 from $10 and keeps an...

19d ago

IOBT

IO Biotech reports expanded Cylembio results

IO Biotech (IOBT) presented detailed results from its global Phase 3 trial of Cylembio, in combination with Merck’s...

21d ago

MRK

IOBT

IO Biotech downgraded to Equal Weight from Overweight at Morgan Stanley

Morgan Stanley downgraded IO Biotech (IOBT) to Equal Weight from Overweight with a price target of 39c, down...

1M ago

IOBT

Hold Rating for IO Biotech Amid Regulatory and Financial Challenges

In a report released yesterday, Michael Ulz from Morgan Stanley downgraded IO Biotech to a Hold, with a...

1M ago

IOBT

IO Biotech downgraded to Hold from Buy at TD Cowen

TD Cowen downgraded IO Biotech (IOBT) to Hold from Buy without a price target after the FDA recommended...

1M ago

IOBT

IO Biotech downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Emily Bodnar downgraded IO Biotech (IOBT) to Neutral from Buy with no price target Published...

1M ago

IOBT

H.C. Wainwright downgrades IO Biotech after FDA recommends another Phase 3 trial

As previously reported, H.C. Wainwright downgraded IO Biotech (IOBT) to Neutral from Buy with no price target after...

1M ago

IOBT

FDA Recommends Against IO Biotech’s Cylembio Application

IO Biotech ( ($IOBT) ) has shared an announcement. On September 25, 2025, IO Biotech‘s Board of Directors...

1M ago

IOBT

IO Biotech says FDA reccomends not submitting BLA based on IOB-013 trial data

IO Biotech (IOBT) provided an update on the regulatory pathway for Cylembiofollowing a pre-BLA meeting with the U.S....

1M ago

IOBT

IO Biotech implements plan to conserve capital, 50% reduction in full-time staff

The company is implementing a plan to conserve capital while it pursues a pathway to regulatory approval for...

1M ago

IOBT

IO Biotech Reports Q2 2025 Financial Results

Io Biotech, Inc. ( ($IOBT) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

IOBT

IO Biotech’s Cylembio Shows Promise Despite Missed Endpoint, Buy Rating Affirmed

IO Biotech, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from...

3M ago

IOBT

Promising Phase 3 Results and Strategic FDA Engagement Bolster Buy Rating for IO Biotech

IO Biotech, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from...

3M ago

IOBT

IOBT FAQ

What was IO Biotech’s price range in the past 12 months?

IO Biotech lowest stock price was $0.32 and its highest was $2.79 in the past 12 months.

What is IO Biotech’s market cap?

IO Biotech’s market cap is $55.54M.

When is IO Biotech’s upcoming earnings report date?

IO Biotech’s upcoming earnings report date is Nov 05, 2025 which is 5 days ago.

How were IO Biotech’s earnings last quarter?

IO Biotech released its earnings results on Aug 14, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.356 by -$0.044.

Is IO Biotech overvalued?

According to Wall Street analysts IO Biotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does IO Biotech pay dividends?

IO Biotech does not currently pay dividends.

What is IO Biotech’s EPS estimate?

IO Biotech’s EPS estimate is -0.31.

How many shares outstanding does IO Biotech have?

IO Biotech has 65,880,910 shares outstanding.

What happened to IO Biotech’s price movement after its last earnings report?

IO Biotech reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.356. Following the earnings report the stock price went up 5.952%.

Which hedge fund is a major shareholder of IO Biotech?

Among the largest hedge funds holding IO Biotech’s share is RA Capital Management. It holds IO Biotech’s shares valued at 0.

IO Biotech Stock Smart Score

Underperform

Fundamentals

Return on Equity

-212.51%

Trailing 12-Months

Asset Growth

-62.03%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

IO Biotech

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

IO Biotech (IOBT) Earnings & Revenues

Historic Earnings Reports

IOBT Stock 12 Month Forecast

Average Price Target

$1.70

▲(88.89% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","-1":"-$1","0.25":"$0.25","1.5":"$1.5","2.75":"$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.39</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.36,0.563076923076923,0.7661538461538462,0.9692307692307692,1.1723076923076925,1.3753846153846156,1.5784615384615384,1.7815384615384615,1.9846153846153847,2.187692307692308,2.390769230769231,2.593846153846154,2.796923076923077,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.36,0.46307692307692305,0.5661538461538461,0.6692307692307692,0.7723076923076923,0.8753846153846153,0.9784615384615384,1.0815384615384613,1.1846153846153844,1.2876923076923075,1.3907692307692305,1.4938461538461536,1.5969230769230767,{"y":1.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.36,0.3623076923076923,0.3646153846153846,0.3669230769230769,0.36923076923076925,0.37153846153846154,0.37384615384615383,0.37615384615384617,0.37846153846153846,0.38076923076923075,0.3830769230769231,0.3853846153846154,0.3876923076923077,{"y":0.39,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.76,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >